Search

Your search keyword '"Tonin, Patricia N"' showing total 452 results

Search Constraints

Start Over You searched for: Author "Tonin, Patricia N" Remove constraint Author: "Tonin, Patricia N"
452 results on '"Tonin, Patricia N"'

Search Results

1. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis

2. Single-cell DNA sequencing—a potential dosimetric tool

3. A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene

5. Investigating the causal role of MRE11A p.E506* in breast and ovarian cancer

7. Supplementary Table 1 from Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy

8. Data from Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy

9. Supplementary Table 1 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a BRCA1/2 French Canadian Founder Mutation

10. Data from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a BRCA1/2 French Canadian Founder Mutation

11. Supplementary Table 5 from Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy

12. Supplementary Data Method and Figures from Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy

13. Supplementary Table 2 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a BRCA1/2 French Canadian Founder Mutation

14. Supplementary Table 1A-B from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a BRCA1/2 French Canadian Founder Mutation

15. Supplementary Table 4 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a BRCA1/2 French Canadian Founder Mutation

16. Supplementary Table 3 from Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy

17. Supplementary Table 2 from Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy

18. Supplementary Table 3 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a BRCA1/2 French Canadian Founder Mutation

19. Supplementary Table 4 from Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy

20. Supplementary figures from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

21. Data from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

22. Data from Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma

23. Supplementary Table 3 from Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma

24. Supplementary Tables and Figures from Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma

25. Supplementary Table 2 from Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma

27. Supplemental Tables S1-S5 from The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers

28. Supplementary Figure 1 from A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity

29. Data from A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity

30. Data from The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers

31. Supplemental Figures S1-S8 from The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers

32. Supplemental Figure Legends from The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers

33. Supplementary Figure Legends 1-2 from A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity

36. Supplementary Figure 2 from A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity

37. Supplementary Table 2 from A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity

39. Supplementary Table 1 from A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity

42. Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases

43. Molecular Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene

44. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers

45. The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population

46. Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic BRCA1 Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic BRCA1 and BRCA2 Variants

48. Analysis of PALB2/FANCN-Associated Breast Cancer Families

Catalog

Books, media, physical & digital resources